MedTrace Logo

ENERGI-F701 for Female Hair Loss Treatment

NCT03351322 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2020-11-24

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.

Conditions

Interventions

DRUG

ENERGI-F701

ENERGI-F701 are applied for treatment of hair loss.

DRUG

Regaine

Regaine are applied for treatment of hair loss.

Sponsors & Collaborators

  • A2 Healthcare Taiwan Corporation

    collaborator INDUSTRY

  • Energenesis Biomedical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-23
Primary Completion
2019-11-29
Completion
2019-12-26

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03351322 on ClinicalTrials.gov